

HSE – Medicines Management Programme (MMP)



Medicines Management Programme

The HSE-Medicines Management Programme (MMP) aims to promote safe, effective and cost-effective prescribing in Ireland. Information on MMP initiatives is available on www.hse.ie/mmp

HSE-MMP Preferred Drugs

Therapeutic Area	☑ HSE-MMP Preferred Drug
Angiotensin-Converting Enzyme (ACE) Inhibitor	Ramipril
Angiotensin-II Receptor Blocker (ARB)	Candesartan
Beta Blocker	Bisoprolol
Calcium Channel Blocker (CCB)	Amlodipine
Oral Anticoagulant	Warfarin
Direct Oral Anticoagulant (DOAC)	Apixaban
Proton Pump Inhibitor (PPI)	Pantoprazole
Selective Serotonin Reuptake Inhibitor (SSRI)	Sertraline
Serotonin Noradrenaline Reuptake Inhibitor (SNRI)	Venlafaxine
Statin	Atorvastatin
Urology (Urinary incontinence, frequency, overactive bladder)	Tolterodine extended release

HSE-MMP Preferred Standard Oral Nutritional Supplements (ONS)

List A: Powdered ONS (*Aymes Shake/with Fibre, Aymes Shake Compact, Complan Shake, Ensure Shake, Foodlink Complete/with Fibre, Fresubin Powder Extra*) and Compact & Mini Drink sip feeds (*Altraplen Compact, Ensure Compact, Fortisip Compact/with Fibre, Fresubin 2Kcal Mini Drink/with Fibre*).

HSE-MMP Preferred Blood Glucose Test Strips (BGTS)

The HSE-MMP has identified preferred BGTS with associated meters for adults with type 1 and type 2 diabetes mellitus. A list of preferred BGTS with associated meters was identified to ensure that there are a variety of options available to patients and prescribers. The HSE-MMP recognises the potential for a reduction in expenditure on BGTS by increased utilisation of preferred BGTS.

Prescribing and Cost Guidance: Dry Eye Syndrome

The HSE-MMP has completed a review of the treatment of dry eye syndrome (DES) and published a Prescribing and Cost Guidance document. The guidance document and associated tips and tools recommend first-line preparations based on clinical evidence and cost, and are intended to promote best practice and aid appropriate prescribing for DES.

Managed Access Protocols (MAPs) are in place for a wide variety of medicines in order to facilitate access for patients. A MAP outlines the criteria that must be satisfied for a patient to be recommended for reimbursement of the medicine. Examples include:

- Community Drug Schemes: liraglutide (Saxenda®), rivaroxaban 2.5 mg.
- High Tech Arrangement: medicines for the prophylaxis of chronic migraine, medicines for moderate-to-severe atopic dermatitis, dupilumab (Dupixent®) for severe asthma, inotersen (Tegsedi®), lanadelumab (Takhzyro®), risdiplam (Evrysdi®), tafamidis (Vyndaqel®), teduglutide (Revestive®), delta-9-tetrahydrocannabinol/cannabidiol (Sativex®).

Further information on all MMP initiatives is available on www.hse.ie/mmp